

Heavy Menstrual Bleeding (update) Committee meeting

Date: 6th April 2017

Location: RCOG

Minutes: Final

Committee members present:	
Mohamed Mehasseb (Chair) (MM)	(Present for notes 1 – 6)
Alice Pritchard (AP)	(Present for notes 1 – 6)
Belinda Champion (BC)	(Present for notes 1 – 6)
Christine Corrin (CC)	(Present for notes 1 – 6)
Gillian Smith (GS)	(Present for notes 1 – 6)
Justin Clark (via telephone from 14.30) (JC)	(Present for notes 1 – 6)
Jonathan Lord (JL)	(Present for notes 1 – 6)
Nathasha Waters (NW)	(Present for notes 1 – 6)
Rachel Brown (RB)	(Present for notes 1 – 6)
Ugochi Nwulu (from 10.30) (UN)	(Present for notes 2 – 6)

In attendance:		
Clifford Middleton	NICE Guidelines Commissioning Manager	(Present for notes 1 – 6)
Lee Walker	NICE Business Analyst	(Present for notes 1 – 6)
Lyn Knott	NICE Senior Medical Editor	(Present for notes 1 – 6)
Amy Burt	NGA Assistant Systematic Reviewer	(Present for notes 1 – 6)
Anne Carty	NGA Project Manager	(Present for notes 1 – 6)
Kelly Williams	NGA Assistant Systematic Reviewer	(Present for notes 1 – 6)
Melanie Davies	NGA Clinical Advisor	(Present for notes 1 – 6)
Paul Jacklin	NGA Senior Health Economist and Interim Guideline Lead	(Present for notes 1 – 6)
Gemma Villanueva	NGA Senior Systematic Reviewer	(Present for notes 1 – 6)

4.0.03 DOC Cmte minutes

Maija Kallioinen	NGA Systematic Reviewer	(Present for notes 1 – 6)
Hugo Pedder	NGA Statistician	(Present for notes 1 – 6)

Apologies	
Gillian Smith (GS)	Committee member
Clifford Middleton	NICE Guideline Commissioning Manager

1. Welcome and objectives for the meeting

The Chair's welcomed Committee members and attendees to the 4th meeting on Heavy Menstrual Bleeding. The Committee members and attendees introduced themselves.

PJ informed the Committee that apologies had been received which are noted above.

PJ outlined the objectives of the meeting, which included:

- Presentation of the results of the network meta-analysis
- Presentation of the evidence for the treatment of HMB.
- Drafting recommendations for the treatment of HMB

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Heavy Menstrual Bleeding

The Chair asked everyone to verbally declare any interests

Name	Job title, organisation	Declaration of Interest	Type of interest	Decision taken
Hugo Pedder	NGA statistician	Working on a project for University of Bristol which is funded by Pfizer who make one of the drugs included in the NMA	Non- personal, specific financial interest	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests

4.0.03 DOC Cmte minutes

declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced MK who presented the result of the review on the management of HMB. MK took questions from the group.

The Chair introduced HP who presented the results of the network meta-analysis. HP took questions from the group.

The Chair introduced PJ who gave a presentation on the health economic model. PJ took questions from the group.

5. Questions and discussion

The Committee discussed working in topic groups to finalise the recommendations and rationale and impact sections of the guideline.

The Committee discussed the results of the network meta-analysis and the evidence found on the treatment of HMB and drafted recommendations.

6 Any other business

The Chair reminded the Committee that next meeting will be on 11th and 12th May 2017. The chair thanked the committee and closed the meeting.

Date of next meeting: 11th and 12th May 2017

Location of next meeting: RCOG, London